Ainhoa Iglesias Ara1, Meng Xia, Komal Ramani, José M Mato, Shelly C Lu. 1. Division of Gastroenterology and Liver Diseases, University of Southern California Research Center for Liver Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
Abstract
UNLABELLED: We previously showed that S-adenosylmethionine (SAMe) and its metabolite methylthioadenosine (MTA) blocked lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFalpha) expression in RAW (murine macrophage cell line) and Kupffer cells at the transcriptional level without affecting nuclear factor kappa B nuclear binding. However, the exact molecular mechanism or mechanisms of the inhibitory effect were unclear. While SAMe is a methyl donor, MTA is an inhibitor of methylation. SAMe can convert to MTA spontaneously, so the effect of exogenous SAMe may be mediated by MTA. The aim of our current work is to examine whether the mechanism of SAMe and MTA's inhibitory effect on proinflammatory mediators might involve modulation of histone methylation. In RAW cells, we found that LPS induced TNFalpha expression by both transcriptional and posttranscriptional mechanisms. SAMe and MTA treatment inhibited the LPS-induced increase in gene transcription. Using the chromatin immunoprecipitation assay, we found that LPS increased the binding of trimethylated histone 3 lysine 4 (H3K4) to the TNFalpha promoter, and this was completely blocked by either SAMe or MTA pretreatment. Similar effects were observed with LPS-mediated induction of inducible nitric oxide synthase (iNOS). LPS increased the binding of histone methyltransferases Set1 and myeloid/lymphoid leukemia to these promoters, which was unaffected by SAMe or MTA. The effects of MTA in RAW cells were confirmed in vivo in LPS-treated mice. Exogenous SAMe is unstable and converts spontaneously to MTA, which is stable and cell-permeant. Treatment with SAMe doubled intracellular MTA and S-adenosylhomocysteine (SAH) levels. SAH also inhibited H3K4 binding to TNFalpha and iNOS promoters. CONCLUSION: The mechanism of SAMe's pharmacologic inhibitory effect on proinflammatory mediators is mainly mediated by MTA and SAH at the level of histone methylation.
UNLABELLED: We previously showed that S-adenosylmethionine (SAMe) and its metabolite methylthioadenosine (MTA) blocked lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFalpha) expression in RAW (murine macrophage cell line) and Kupffer cells at the transcriptional level without affecting nuclear factor kappa B nuclear binding. However, the exact molecular mechanism or mechanisms of the inhibitory effect were unclear. While SAMe is a methyl donor, MTA is an inhibitor of methylation. SAMe can convert to MTA spontaneously, so the effect of exogenous SAMe may be mediated by MTA. The aim of our current work is to examine whether the mechanism of SAMe and MTA's inhibitory effect on proinflammatory mediators might involve modulation of histone methylation. In RAW cells, we found that LPS induced TNFalpha expression by both transcriptional and posttranscriptional mechanisms. SAMe and MTA treatment inhibited the LPS-induced increase in gene transcription. Using the chromatin immunoprecipitation assay, we found that LPS increased the binding of trimethylated histone 3 lysine 4 (H3K4) to the TNFalpha promoter, and this was completely blocked by either SAMe or MTA pretreatment. Similar effects were observed with LPS-mediated induction of inducible nitric oxide synthase (iNOS). LPS increased the binding of histone methyltransferases Set1 and myeloid/lymphoid leukemia to these promoters, which was unaffected by SAMe or MTA. The effects of MTA in RAW cells were confirmed in vivo in LPS-treated mice. Exogenous SAMe is unstable and converts spontaneously to MTA, which is stable and cell-permeant. Treatment with SAMe doubled intracellular MTA and S-adenosylhomocysteine (SAH) levels. SAH also inhibited H3K4 binding to TNFalpha and iNOS promoters. CONCLUSION: The mechanism of SAMe's pharmacologic inhibitory effect on proinflammatory mediators is mainly mediated by MTA and SAH at the level of histone methylation.
Authors: J M Mato; J Cámara; J Fernández de Paz; L Caballería; S Coll; A Caballero; L García-Buey; J Beltrán; V Benita; J Caballería; R Solà; R Moreno-Otero; F Barrao; A Martín-Duce; J A Correa; A Parés; E Barrao; I García-Magaz; J L Puerta; J Moreno; G Boissard; P Ortiz; J Rodés Journal: J Hepatol Date: 1999-06 Impact factor: 25.083
Authors: Matthew G Guenther; Richard G Jenner; Brett Chevalier; Tatsuya Nakamura; Carlo M Croce; Eli Canaani; Richard A Young Journal: Proc Natl Acad Sci U S A Date: 2005-06-07 Impact factor: 11.205
Authors: Jason E Fish; Charles C Matouk; Alisa Rachlis; Steven Lin; Sharon C Tai; Cheryl D'Abreo; Philip A Marsden Journal: J Biol Chem Date: 2005-05-03 Impact factor: 5.157
Authors: Maria Lauda Tomasi; Ivan Tomasi; Komal Ramani; Rosa Maria Pascale; Jun Xu; Pasquale Giordano; José M Mato; Shelly C Lu Journal: Hepatology Date: 2012-07-12 Impact factor: 17.425
Authors: Farah Esfandiari; Valentina Medici; Donna H Wong; Soumia Jose; Maryam Dolatshahi; Eoin Quinlivan; Sanjana Dayal; Steven R Lentz; Hidekazu Tsukamoto; Yue Hua Zhang; Samuel W French; Charles H Halsted Journal: Hepatology Date: 2010-03 Impact factor: 17.425
Authors: Jun Li; Fawzia Bardag-Gorce; Joan Oliva; Jennifer Dedes; Barbara A French; Samuel W French Journal: Genes Nutr Date: 2009-12-04 Impact factor: 5.523
Authors: Shelly C Lu; Komal Ramani; Xiaopeng Ou; Mark Lin; Victor Yu; Kwangsuk Ko; Ryan Park; Teodoro Bottiglieri; Hidekazu Tsukamoto; Gary Kanel; Samuel W French; José M Mato; Rex Moats; Edward Grant Journal: Hepatology Date: 2009-08 Impact factor: 17.425